Characteristic | Non-cART | cART* | Total |
---|---|---|---|
 | N = 2,467 (21.1%) | N = 9,226 (78.9%) | N = 11,693 (100%) |
TB patients | 103 (4.2%) | 130 (1.4%) | 233 (2%) |
Gender | Â | Â | Â |
   Male | 1.994 (80.8%) | 7,394 (80.2%) | 9,388 (80.3%) |
   Female | 473 (19.2%) | 1,831 (19.9%) | 2,304 (19.7%) |
Age at enrollment, years | Â | Â | Â |
Median [IQR] | 35 [29–42] | 39 [32–46] | 38 [31–45] |
   ≤38 | 1,468 (59.6%) | 4,338 (47.1%) | 5,806 (49.7%) |
   >38†| 994 (40.4%) | 4,873 (52.9%) | 5,867 (50.3%) |
Geographical origin | Â | Â | Â |
   Germany | 1,731 (72.1%) | 6,631 (73.0%) | 8,362 (72.8%) |
   Sub-Saharan Africa | 255 (10.6%) | 1,066 (11.7%) | 1,321 (11.5%) |
HIV-transmission risk group | Â | Â | Â |
   MSM | 1,339 (60.3%) | 4,768 (57.8%) | 6,107 (58.4%) |
   Other | 881 (39.7%) | 3,477 (42.8%) | 4,358 (41.6%) |
CD4+ cell count at enrollment in the cohort, cells/μl |  |  |  |
Median [IQR] | 492 [349–663] | 273 [118–453] | 320 [146–508] |
   >200 | 2,054 (89.1%) | 5,467 (61.9%) | 7,521 (67.6%) |
   ≤200†| 251 (10.9%) | 3,362 (38.1%) | 3,613 (32.5%) |
Viral load at enrollment in the cohort, log10 copies/ml | Â | Â | Â |
Median [IQR] | 4.2 [3.4 – 4.8] | 4.5 [3.1 – 5.2] | 4.4 [3.3 – 5.7] |
   <5 | 1,769 (72.9%) | 5,845 (68.1%) | 7,614 (70.5%) |
   ≥5†| 446 (20.1%) | 2,737 (31.9%) | 3,183 (29.5%) |
Calendar year of enrollment | Â | Â | Â |
   2001 | 147 (5.9%) | 765 (8.2%) | 912 (7.7%) |
   2002 | 166 (6.7%) | 832 (9.0%) | 998 (8.4%) |
   2003 | 178 (7.2%) | 839 (10.1%) | 1,017 (8.7%) |
   2004 | 205 (8.3%) | 928 (10.1%) | 1,133 (9.7%) |
   2005 | 213 (8.6%) | 908 (9.8%) | 1,121(9.5%) |
   2006 | 225 (9.1%) | 842 (9.1%) | 1,067 (9.1%) |
   2007 | 251(10.2%) | 893 (10.6%) | 1,144 (9.8%) |
   2008 | 217 (8.8%) | 883 (9.5%) | 1,100 (9.4%) |
   2009 | 249 (10.1%) | 835 (9.1%) | 1,084 (9.3%) |
   2010 | 278 (11.3%) | 811 (8.8%) | 1,089 (9.3%) |
   2011 | 338 (13.7%) | 690 (7.5%) | 1,028 (8.8%) |
Length of follow-up (person-years) | Â | Â | Â |
Median [IQR] | 1.2 [0.3-2.8] | 3.1 [1.3-5.9] | 2.5 [1.1-5.3] |